Shortened poly-N-acetylglucosamine nanofibers stimulate host defensin expression to reduce bacterial loads without triggering antibiotic resistance.
Amorphous solid dispersion improves Aprepitant solubility while avoiding manufacturing complexity.
Melt extrusion creates a homogeneous itraconazole and hydroxypropyl methylcellulose solid dispersion for enhanced dissolution.
Ionizable cationic lipid analogs form stable complexes with nucleic acids for efficient intracellular delivery.
Implantable biomaterials release immunoadjuvant-loaded nanoparticles to activate immune responses against tumors while minimizing damage to healthy tissues.
Bifunctional polyethylene glycol linkers on gold SERS nanotags prevent direct biological molecule adsorption, ensuring reproducible signal detection in vivo.
Replacing lyophilization with aseptic spray drying reduces energy consumption while producing amorphous tobramycin sulfate powder suitable for intravenous use.
Replacing hydrophobic ligands with ionic dendritic polymers enhances aqueous solubility and biocompatibility of up-converting nanoparticles.
Complexed antibody-substrate nano-particulates bind circulating chromatin fragments, reducing pathological burden without invasive ex-vivo procedures.
Selective BRD4 inhibitors block airway inflammation while avoiding blood-brain barrier penetration to prevent neurological adverse effects.
A mitotane dry emulsion formulation using cyclodextrins enhances oral bioavailability through inclusion complex formation.
Isolating 13 specific glycerides from Coix seed oil resolves quality control contradictions while enabling tumor cell inhibition.
Hydrophobic ion-pairing complexes associate with biodegradable polymeric microparticles to enable sustained release of levo-alpha-acetylmethadol.
High-pressure homogenization reduces 17-OHPC particle size while preserving crystalline structure and minimizing contamination.
Replacing lactose with non-reducing sugars stabilizes thyroid hormone dry powder, preventing degradation during long-term storage.
Modified platelets deliver checkpoint inhibitors to bone marrow leukemia cells.